EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adjuvant Icotinib in EGFR-mutated stage IB non-small cell lung cancer with high-risk factors: A retrospective case series

Mengzhi Cheng iD, Jianbin Zhang iD, Lili Jin, Caihua Yu, Zhonghai Xie, Dong Li, Qinhua Gu, Qibin Shen

PLOS One · 2025

DOI: 10.1371/journal.pone.0337237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Mengzhi Cheng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang, …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Crown Ethers, Lung Neoplasms, Quinazolines. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Joint Funds of the Zhejiang Provincial Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary results of the CORIN trial indicated that, compared with chemotherapy, icotinib significantly improved 3-year disease-free survival (DFS) in patients with Epidermal Growth Factor Receptor (EGFR)-mutated stage IB non-small cell lung cancer (NSCLC). However, evidence regarding the outcomes of adjuvant icotinib in patients with high-risk factors remains limited. This retrospective study evaluated the efficacy and safety of adjuvant icotinib in patients with EGFR-mutated high-risk stage IB NSCLC. We enrolled 37 patients with completely resected EGFR-mutated high-risk stage IB NSCLC. The median follow-up time was 31 months, and the 3-year DFS rate was 91.4%. Two patients experienced disease recurrence and were successfully switched to osimertinib upon identification of an EGFR (T790M) mutation. Although overall survival (OS) and central nervous system (CNS)-DFS data were not mature, no deaths or central nervous system metastases were observed by the end of follow-up. 29 (78.4%) patients experienced grade 1–2 adverse events (AEs), no grade 3 or higher AEs occurred. This study suggests a potential DFS benefit and well-tolerated profile of adjuvant icotinib in patients with EGFR-mutated high-risk stage IB NSCLC. However, longer-term follow-up is necessary to assess the long-term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCrown EthersLung NeoplasmsQuinazolinesAntineoplastic AgentsHumansMaleFemaleErbB ReceptorsMiddle AgedRetrospective StudiesAgedMutationRisk FactorsAdultChemotherapy, AdjuvantNeoplasm StagingDisease-Free Survival

Substanzen

icotinibCrown EthersErbB ReceptorsEGFR protein, humanQuinazolinesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang, China.
  • Department of Thoracic Surgery, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China.
  • Department of Central Laboratory, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang, China.
  • Department of Central Laboratory, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China.

ORCID-Profile: Mengzhi Cheng, Jianbin Zhang

Förderung

  • the Joint Funds of the Zhejiang Provincial Natural Science Foundation of China

Zitieren

APA

Cheng, M., Zhang, J., Jin, L., Yu, C., Xie, Z., Li, D., Gu, Q., & Shen, Q. (2025). Adjuvant Icotinib in EGFR-mutated stage IB non-small cell lung cancer with high-risk factors: A retrospective case series. PLOS One. https://doi.org/10.1371/journal.pone.0337237

Vancouver

Cheng M, Zhang J, Jin L, Yu C, Xie Z, Li D, et al. Adjuvant Icotinib in EGFR-mutated stage IB non-small cell lung cancer with high-risk factors: A retrospective case series. PLOS One. 2025. doi:10.1371/journal.pone.0337237

BibTeX
@article{Cheng2025,
  author = {Cheng, Mengzhi and Zhang, Jianbin and Jin, Lili and Yu, Caihua and Xie, Zhonghai and Li, Dong and Gu, Qinhua and Shen, Qibin},
  title = {Adjuvant Icotinib in EGFR-mutated stage IB non-small cell lung cancer with high-risk factors: A retrospective case series},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0337237}
}
Kostenlos starten →